These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16061895)

  • 21. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation.
    Drummond MF; Aguiar-Ibanez R; Nixon J
    Singapore Med J; 2006 Jun; 47(6):456-61; quiz 462. PubMed ID: 16752012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost utility analyses in international disaster responses-where are they?
    Zoraster R
    Prehosp Disaster Med; 2012 Apr; 27(2):198-203. PubMed ID: 22595691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
    Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
    Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
    Zhou T; Chen Z; Li H; Xie F
    Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of the National truth campaign to prevent youth smoking.
    Holtgrave DR; Wunderink KA; Vallone DM; Healton CG
    Am J Prev Med; 2009 May; 36(5):385-8. PubMed ID: 19211214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The State of Cost-Utility Analyses in Asia: A Systematic Review.
    Thorat T; Lin PJ; Neumann PJ
    Value Health Reg Issues; 2015 May; 6():7-13. PubMed ID: 29698196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generalizability of cost-utility analyses across countries and settings.
    Ginsberg GM
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):845-52. PubMed ID: 24182605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.
    Stone PW; Teutsch S; Chapman RH; Bell C; Goldie SJ; Neumann PJ
    Am J Prev Med; 2000 Jul; 19(1):15-23. PubMed ID: 10865159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the dollar value of health outcomes from drug-abuse interventions.
    French MT; Mauskopf JA; Teague JL; Roland EJ
    Med Care; 1996 Sep; 34(9):890-910. PubMed ID: 8792779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
    Neumann PJ; Fang CH; Cohen JT
    Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas.
    Neumann PJ; Farquhar M; Wilkinson CL; Lowry M; Gold M
    Am J Public Health; 2016 Dec; 106(12):2205-2207. PubMed ID: 27631752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Evidence Sources for Health-Related Quality of Life in Cost-Utility Analysis of Pharmaceuticals in Japan.
    Azuma MK; Ikeda S
    Value Health Reg Issues; 2014 May; 3():190-196. PubMed ID: 29702927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion of published cost-utility analyses in the field of health policy and practice.
    Sonnad SS; Greenberg D; Rosen AB; Neumann PJ
    Int J Technol Assess Health Care; 2005; 21(3):399-402. PubMed ID: 16110721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US.
    Ladapo JA; Neumann PJ; Keren R; Prosser LA
    Pharmacoeconomics; 2007; 25(10):817-28. PubMed ID: 17887804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses.
    Bell CM; Chapman RH; Stone PW; Sandberg EA; Neumann PJ
    Med Decis Making; 2001; 21(4):288-94. PubMed ID: 11475385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.